Top 5 Target	Count

CD276 x Top I	1
sGC(Soluble guanylate cyclase)	1
PCSK9(Proprotein convertase subtilisin kexin type 9)	1
LILRB2(Leukocyte immunoglobulin-like receptor subfamily B member 2)	1
F11(Coagulation factor XI)	1

Drugs associated with MSD R&D (China) Co. Ltd.

Sacituzumab tirumotecan

Target

Trop-2

Mechanism

Trop-2 inhibitors

Active Org.

Merck Sharp & Dohme Corp. [+5]

Originator Org.

Sichuan Kelun Pharmaceutical Co., Ltd.

Active Indication

Triple Negative Breast Cancer [+39]

Inactive Indication-

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date22 Nov 2024

Sotatercept

Target

ACVR2A x activin receptor

Mechanism

ACVR2A modulators [+1]

Active Org.

MSD R&D (China) Co. Ltd. [+9]

Originator Org.

Acceleron Pharma, Inc.

Active Indication

Depressive Disorder [+5]

Inactive Indication

Anemia, Diamond-Blackfan [+11]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date26 Mar 2024

Gefapixant Citrate

Target

P2X3 receptor

Mechanism

P2X3 receptor antagonists

Active Org.

MSD KK [+1]

Originator Org.

F. Hoffmann-La Roche Ltd.

Active Indication

Unexplained chronic cough [+1]

Inactive Indication

Acute onset cough [+13]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date20 Jan 2022

156

Clinical Trials associated with MSD R&D (China) Co. Ltd.

CTR20244069

/ RecruitingPhase 3

一项评价帕博利珠单抗与透明质酸酶复方制剂（MK-3475A）皮下给药对比帕博利珠单抗静脉给药一线治疗PD-L1 TPS≥50%的转移性非小细胞肺癌受试者的药代动力学和安全性的III期、随机、开放临床研究

[Translation] A phase III, randomized, open-label clinical study to evaluate the pharmacokinetics and safety of subcutaneous administration of pembrolizumab and hyaluronidase combination (MK-3475A) versus intravenous administration of pembrolizumab as first-line treatment for patients with metastatic non-small cell lung cancer with PD-L1 TPS ≥ 50%

评估MK-3475A皮下给药与帕博利珠单抗静脉给药作为转移性非小细胞肺癌受试者一线治疗时的药代动力学和安全性

[Translation]

To evaluate the pharmacokinetics and safety of subcutaneous MK-3475A versus intravenous pembrolizumab as first-line treatment in subjects with metastatic non-small cell lung cancer

Start Date20 Dec 2024

Sponsor / Collaborator

MSD R&D (China) Co. Ltd.

[+2]

CTR20244342

/ RecruitingPhase 2

一项在接受标准治疗的动脉性肺动脉高压（PAH）患者中，评估Sotatercept（MK-7962）按体重给药或按体重区间给药的药代动力学和安全性的II期、多中心、单盲、随机研究

[Translation] A Phase II, multicenter, single-blind, randomized study to evaluate the pharmacokinetics and safety of weight-based dosing or weight-based interval dosing of Sotatercept (MK-7962) in patients with pulmonary arterial hypertension (PAH) receiving standard therapy

主要目的：1) 评估sotatercept按体重区间给药相对于按体重给药，在稳态下多次（维持剂量）给药后的稳态全身暴露量。2) 评估sotatercept治疗24周的安全性和耐受性。次要目的：评估sotatercept按体重区间给药相对于按体重给药，在起始剂量给药后的全身暴露量。

[Translation]

Primary objectives: 1) To evaluate the steady-state systemic exposure of sotatercept after multiple (maintenance dose) administration at steady state when administered by weight intervals compared to when administered by weight. 2) To evaluate the safety and tolerability of sotatercept for 24 weeks. Secondary objectives: To evaluate the systemic exposure of sotatercept after the initial dose when administered by weight intervals compared to when administered by weight.

Start Date13 Dec 2024

Sponsor / Collaborator

MSD R&D (China) Co. Ltd.

[+2]

CTR20242278

/ RecruitingPhase 3

一项评估MK-1084联合帕博利珠单抗相比较帕博利珠单抗联合安慰剂一线治疗PD-L1 TPS≥50%的KRAS G12C突变转移性非小细胞肺癌受试者的III期、随机、双盲、多中心研究

[Translation] A Phase III, randomized, double-blind, multicenter study evaluating MK-1084 plus pembrolizumab versus pembrolizumab plus placebo as first-line treatment for patients with KRAS G12C-mutated metastatic non-small cell lung cancer and PD-L1 TPS ≥ 50%

在新诊断的转移性NSCLC受试者中比较MK-1084+帕博利珠单抗与帕博利珠单抗+安慰剂的有效性和安全性。

[Translation]

To compare the efficacy and safety of MK-1084 plus pembrolizumab versus pembrolizumab plus placebo in subjects with newly diagnosed metastatic NSCLC.

Start Date24 Oct 2024

Sponsor / Collaborator

MSD R&D (China) Co. Ltd.

100 Clinical Results associated with MSD R&D (China) Co. Ltd.

0 Patents (Medical) associated with MSD R&D (China) Co. Ltd.

Literatures (Medical) associated with MSD R&D (China) Co. Ltd.

01 Sep 2024·BMJ Open

Barriers and facilitators to implementing imaging-based diagnostic artificial intelligence-assisted decision-making software in hospitals in China: a qualitative study using the updated Consolidated Framework for Implementation Research

Article

Author: Liao, Xiwen ; Zhang, Jun ; Liu, Larry ; Yao, Chen ; Jin, Feifei

ObjectivesTo identify the barriers and facilitators to the successful implementation of imaging-based diagnostic artificial intelligence (AI)-assisted decision-making software in China, using the updated Consolidated Framework for Implementation Research (CFIR) as a theoretical basis to develop strategies that promote effective implementation.DesignThis qualitative study involved semistructured interviews with key stakeholders from both clinical settings and industry. Interview guide development, coding, analysis and reporting of findings were thoroughly informed by the updated CFIR.SettingFour healthcare institutions in Beijing and Shanghai and two vendors of AI-assisted decision-making software for lung nodules detection and diabetic retinopathy screening were selected based on purposive sampling.ParticipantsA total of 23 healthcare practitioners, 6 hospital informatics specialists, 4 hospital administrators and 7 vendors of the selected AI-assisted decision-making software were included in the study.ResultsWithin the 5 CFIR domains, 10 constructs were identified as barriers, 8 as facilitators and 3 as both barriers and facilitators. Major barriers included unsatisfactory clinical performance (Innovation); lack of collaborative network between primary and tertiary hospitals, lack of information security measures and certification (outer setting); suboptimal data quality, misalignment between software functions and goals of healthcare institutions (inner setting); unmet clinical needs (individuals). Key facilitators were strong empirical evidence of effectiveness, improved clinical efficiency (innovation); national guidelines related to AI, deployment of AI software in peer hospitals (outer setting); integration of AI software into existing hospital systems (inner setting) and involvement of clinicians (implementation process).ConclusionsThe study findings contributed to the ongoing exploration of AI integration in healthcare from the perspective of China, emphasising the need for a comprehensive approach considering both innovation-specific factors and the broader organisational and contextual dynamics. As China and other developing countries continue to advance in adopting AI technologies, the derived insights could further inform healthcare practitioners, industry stakeholders and policy-makers, guiding policies and practices that promote the successful implementation of imaging-based diagnostic AI-assisted decision-making software in healthcare for optimal patient care.

06 Mar 2024·Perspectives in Psychiatric Care

Mental and Physical Symptoms and Perceived Health Risks of Pregnant and Postpartum Women following the Significant Shift in COVID-19 Management in China: A Cross-Sectional Survey

Author: Shen, Qing ; Su, Yu-Qiang ; Liu, Shou ; Chen, Chang ; Wang, Yan-Ni ; Lu, Li ; Lai, Sha ; Zhang, TianTian ; Ren, Duo-Mei ; Hu, Ying ; Yan, Yi-Zhu ; Ma, Bing-Cun ; Zhou, Zhongliang

Background. There was a remarkable downgrade in China’s COVID-19 response strategies in January 2023. The COVID-19 infection rate grew rapidly in the early stages following the management policy shift. This study attempted to explore the associations between SARS-CoV-2 infection and mental or physical health status in pregnant and postpartum women and the role of perceived health risks and family members’ SARS-CoV-2 infection status on these associations by capturing the impact of policy shifts in a short period of time. Methods. This cross-sectional study with a random sample from a convenience sample of hospitals was conducted in pregnant and postpartum women in January 2023. Standardized assessment tools were employed to assess anxiety, depressive and physical symptoms, and feelings of hopelessness. Hierarchical multiple logistic regressions were conducted to examine the mechanisms of associations of interests by including a range of sociodemographic factors, self-perceived health, SARS-CoV-2 infection status, and perceived health risks as covariates. Results. Of the 1,013 pregnant and postpartum women aged 32.0 ± 0.3 years, 58.2% (n = 590) were diagnosed with COVID-19, and 49.4% (n = 500) had family members who were infected with SARS-CoV-2. Nearly 98% of the included participants took measures to prevent SARS-CoV-2 infection. A COVID-19 diagnosis was positively associated with feelings of hopelessness (OR = 1.68, 95% CI: 1.20–2.35), probable anxiety (OR = 6.42, 95% CI: 2.18–24.61), possible depression (OR = 2.56, 95% CI: 1.07–6.70), and physical symptoms (OR = 6.28, 95% CI: 1.63–42.03) after adjusting for sociodemographic and health characteristics, while the associations presented no statistical significance when family members’ SARS-CoV-2 infection status and perceived health risks were introduced into the models. Conclusions. Our results suggested that pregnant and postpartum women may experience physical and mental health challenges when they or their family members contracted COVID-19 in the context of a considerable shift in COVID-19 management. Early detection of poor health status and its risk factors for vulnerable groups during shifts in health policy and administrative practice is very necessary, and health services, including easy access to psychosocial support and obstetric counselling, should be prioritized.

26 Jan 2024·Medicine

Comparing verum and sham acupoint catgut embedding for adults with obesity: A systematic review and meta-analysis of randomized clinical trials

Review

Author: Zhao, Wei-wei ; Zhang, Qin-hong ; Zhang, Yu-ying ; Mah, Jeffrey Zhong-xue ; Huang, Jia-qi ; Li, Xiao-ling ; Yue, Jin-huan ; Yang, Guan-hu ; Li, Ang ; Wang, Yu-lin

Background:Previous clinical trials have reported that acupoint catgut embedding (ACE) is a useful modality for weight loss. However, no study has specifically investigated the effectiveness and safety of comparing verum and sham ACE in adults with obesity. Thus, this study aimed to evaluate the effectiveness and safety of comparing verum and sham ACE in obese adults.Methods:A comprehensive literature search was conducted in the electronic databases of PUBMED, EMBASE, Cochrane Library, Web of Science, China National Knowledge Infrastructure, Wanfang, China Science and Technology Journal Database, and China Biomedical Literature Service System from inception to April 1, 2022. Randomized clinical trials that focused on evaluating the effectiveness of comparing verum and sham ACE in adults with obesity were included. The primary outcomes included reduction in body weight, body mass index, hip circumference, and waist circumference. The secondary outcomes consisted of a decrease in body fat percentage and the occurrence rate of adverse events. The methodological quality of the included randomized clinical trials was evaluated using the Cochrane Risk-of-bias tool. Statistical analysis was performed using RevMan 5.4 software.Results:Six trials involving 679 adults with obesity were included in this study and entered in the data analysis of systematic review and meta-analysis. Results of the meta-analysis revealed significant reduction in body weight (mean difference [MD] = −1.68, 95% confidence intervals (CI) [−2.34, −1.01], I2 = 51%, P < .001), body mass index (MD = −0.51, 95% CI [−0.81, −0.21], I2 = 74%, P < .001), hip circumference (MD = −1.11, 95% CI [−1.67, −0.55], I2 = 0%, P < .001), waist circumference (MD = −2.42, 95% CI [−3.38, −1.45], I2 = 68%, P < .001), and decrease in body fat percentage (MD = −0.83, 95% CI [−1.30, −0.36], I2 = 16%, P < .001) in comparing verum and sham ACE. However, no significant difference was identified in AEs (odds ratio = 1.53, 95% CI [0.80, 2.95], I2 = 0%, P = .20) between the 2 groups.Conclusion:ACE is effective in the treatment of obesity in adults with safety profile. Further studies with higher quality and larger sample size are warranted to confirm the current findings.

100 Deals associated with MSD R&D (China) Co. Ltd.

100 Translational Medicine associated with MSD R&D (China) Co. Ltd.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 29 Jan 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

IND Application

IND Approval

Phase 1 Clinical

Phase 2 Clinical

Phase 3 Clinical

NDA/BLA

Approved

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Pembrolizumab ( PD-1 )	Metastatic Non-Squamous Non-Small Cell Lung Carcinoma More	Approved
Belzutifan ( HIF-2α )	Neuroendocrine tumor of pancreas More	Approved
Human papillomavirus 9-valent vaccine, recombinant (Merck Sharp & Dohme)	HPV-related carcinoma More	NDA/BLA
Tulisokibart ( VEGI )	Colitis, Ulcerative More	Phase 3
Nemtabrutinib ( BTK C481S )	Small Lymphocytic Lymphoma More	Phase 3

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis